PURPOSE: The ccrcc1-4 transcriptomic subtypes were previously identified on fresh frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value post-nephrectomy/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs). We aimed to extend and validate the ccrcc1-4 classifier on formalin-fixed paraffin-embedded (FFPE) tissues and to validate its prognostic and predictive value across the RCC treatment landscape. EXPERIMENTAL DESIGN: RNA sequencing of tumoral FFPE tissue was performed. A classifier called Clearseq was designed to determine ccrcc1-4 subtypes. Subtypes were correlated with outcome after surgical and systemic therapies. External validation was pursued as well as characterization at single-cell transcriptomic level. RESULTS: A total of 668 tumoral samples (337 primary tumors and 331 metastases) from 364 patients were assigned into ccrcc1, ccrcc2, ccrcc3 and ccrcc4-tumors. The angiogenic ccrcc2-subtype had a favorable prognosis after nephrectomy in localized setting, after cytoreductive nephrectomy and upon metastasectomy with curative intent and was correlated with improved outcome on first-line VEGFR-TKIs. Ccrcc4-tumors were enriched for sarcomatoid features and had the largest treatment benefit on immune checkpoint blockade (ICB) treatment in any line, resulting in overall survival outcomes comparable to those of less aggressive subtypes. These findings were corroborated in a post-nephrectomy cohort, and external cohorts of metastatic patients treated with ICB and/or angiogenesis inhibitors. CONCLUSIONS: We validated the Clearseq classifier to predict ccrcc1-4 molecular subtype on FFPE tissues and confirmed its performance with respect to previous biomarker findings for both surgical and systemic treatment approaches.